Management of Enterococcus faecalis Vesiculitis (Prostatitis)

First‑Line Antimicrobial Regimens

Ampicillin 2 g IV every 4 h plus gentamicin for 4–6 weeks is recommended when the isolate is susceptible to penicillins and aminoglycosides. This combination provides bactericidal activity and reduces therapeutic failure. 1
Penicillin G 18–30 million U/24 h IV combined with gentamicin for 4–6 weeks is an equivalent alternative for susceptible strains. 2

Enterococci, including E. faecalis, exhibit partial resistance to many β‑lactams; β‑lactam monotherapy is not bactericidal and is associated with a high rate of treatment failure. 1

Gentamicin should be given in multiple daily doses (every 8 h) with serum peak ≈ 3 µg/mL and trough < 1 µg/mL to achieve optimal synergistic killing. 3
The aminoglycoside component must be continued through the entire treatment course, unlike regimens for streptococcal infections. 2

Double β‑lactam therapy: Ampicillin 2 g IV q4 h + Ceftriaxone 2 g IV q12 h for 6 weeks. This is appropriate for patients with normal or impaired renal function, cranial nerve VIII dysfunction, or when rapid serum aminoglycoside levels are unavailable. 5

Vancomycin + gentamicin for 6 weeks can be used when β‑lactams are contraindicated, but the β‑lactam + gentamicin combination is preferred because it carries a lower risk of ototoxicity and nephrotoxicity. 7

Linezolid 600 mg IV or PO every 12 h (strong recommendation) achieves microbiological cure in ≈ 86 % and clinical cure in ≈ 81 % of cases. 8
High‑dose daptomycin 8–12 mg/kg/day (alone or combined with a β‑lactam) is an effective alternative for VRE infections. 9

Routine susceptibility testing must include MIC determination for penicillin and vancomycin, and high‑level gentamicin resistance testing (≥ 500 µg/mL) to predict synergistic potential. If resistance to β‑lactams, vancomycin, or aminoglycosides is identified, daptomycin and linezolid susceptibility should be assessed. 3
26–50 % of E. faecalis isolates display high‑level aminoglycoside resistance, rendering aminoglycoside‑containing regimens ineffective and necessitating double β‑lactam therapy. 4

4–6 weeks for infections with symptom duration < 3 months when using ampicillin or penicillin + gentamicin. 5
6 weeks when employing the ampicillin + ceftriaxone double β‑lactam regimen, irrespective of symptom duration. 6
Treatment length should be aligned with correction of the underlying urologic abnormality. 11

Nephrotoxicity is a major concern with gentamicin, especially in elderly or debilitated patients with pre‑existing renal impairment. 3
Streptomycin must be avoided in patients with creatinine clearance < 50 mL/min. 6
Patients whose creatinine clearance falls below 50 mL/min (at baseline or during therapy) should be switched to the double β‑lactam regimen. 5
Required monitoring includes gentamicin serum concentrations (peak and trough) and serial renal function assessments throughout therapy. 3
If the laboratory cannot provide rapid aminoglycoside serum levels, the double β‑lactam regimen should be used instead. 5

Infectious disease specialist consultation is recommended as standard of care for all enterococcal vesiculitis cases. This is particularly important for isolates with high‑level resistance to vancomycin, ampicillin, or aminoglycosides, for VRE infections, and for patients with complex comorbidities or renal dysfunction. 1